KKR Invests $3 Billion in Life Sciences Investor Catalio Capital
Private-equity firm KKR has acquired a minority stake in Catalio Capital Management, a firm specializing in venture-capital and other medical-investment funds. This move reflects a growing trend of private-equity firms entering the life sciences sector by partnering with earlier-stage investors, aiming to capitalize on emerging opportunities in biotechnology highlighted by the Covid-19 pandemic.